Plasmapheresis is indicated as treatment for the immunologic neuropathy associated with which antibody?

Plasmapheresis is a therapeutic procedure primarily used to remove antibodies and inflammatory mediators from the bloodstream. Its indication in immunologic neuropathy is most commonly associated with the presence of antiganglioside antibodies, particularly in conditions such as Guillain-Barré syndrome.

In the context of antiganglioside antibodies, these antibodies target nerve components and are implicated in causing demyelination and autoimmune neuropathy. Plasmapheresis can help in rapidly decreasing the levels of these antibodies, thereby alleviating the symptoms and improving nerve function. This treatment is especially effective in acute or severe cases of neuropathy where quick intervention is necessary to prevent long-term damage.

Other antibodies listed, such as IgG4, anti-dsDNA, and antihistone antibody, are more closely associated with other types of autoimmune diseases and conditions. IgG4 is often related to conditions like IgG4-related disease, while anti-dsDNA is commonly associated with systemic lupus erythematosus (SLE). Antihistone antibodies are typically found in drug-induced lupus. These antibodies do not have the same direct link to an acute neuropathic process that would require plasmapheresis as a treatment strategy.

Therefore, the association of antig